Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002;4 Suppl 3(Suppl 3):S153-8.
doi: 10.1186/ar571. Epub 2002 May 9.

HLA-B27: natural function and pathogenic role in spondyloarthritis

Affiliations
Review

HLA-B27: natural function and pathogenic role in spondyloarthritis

Andrew McMichael et al. Arthritis Res. 2002.

Abstract

The human leukocyte antigen HLA-B27 is strongly associated with development of a group of inflammatory arthritides collectively known as the spondyloarthritides. We have set out to define the natural immunological function of HLA-B27, and then to apply this knowledge to understand its pathogenic role. Human leukocyte antigen class 1 molecules bind antigenic peptides for cell surface presentation to cytotoxic T lymphocytes. HLA-B27 binds and presents peptides from influenza, HIV, Epstein-Barr virus, and other viruses. This leads to vigorous and specific cytotoxic T lymphocyte responses, which play an important role in the body's immune response to these viruses. HLA-B27 thus carries out its natural function highly effectively. Although many theories have been proposed to explain the role of HLA-B27 in the pathogenesis of spondyloarthropathy, we favour those postulating that the pathogenic role of HLA-B27 stems from its natural function. For example, the 'arthritogenic' peptide hypothesis suggests that disease results from the ability of HLA-B27 to bind a unique peptide or a set of antigenic peptides. Additionally, a number of lines of evidence from our laboratory and other laboratories have suggested that HLA-B27 has unusual cell biology. We have recently demonstrated that HLA-B27 is capable of forming disulfide-bonded homodimers. These homodimers are expressed on the cell surface and are ligands for a number of natural killer and related immunoreceptors, expressed on a variety of cell types including natural killer cells, T lymphocytes and B lymphocytes, and members of the monocyte/macrophage lineage. We are currently investigating the possibility that such interactions could be involved in disease pathogenesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Disulfide-bonded HLA-B27 heavy chain homodimers are present in HLA-B*2705 transfected LBL721.220 cells. HC-10 western blot shown under non-reducing (upper panel) and reducing (lower panel) conditions. The left-hand lane shows untransfected 721.220 cells.
Figure 2
Figure 2
Hypothetical molecular model of the HLA-B27 heavy chain homodimer structure. The alpha 1, 2, and 3 domains of two HLA-B27 molecules are shown in ribbon form, bound peptide shown. Orientation: cell surface at bottom of picture.
Figure 3
Figure 3
Hypothetical model for the role of HLA-B27 homodimers in the pathogenesis of spondyloarthritis. NK, natural killer.

References

    1. Brewerton DA, Caffrey M, Hart FD, James DCO, Nichols A, Sturrock RD. Ankylosing spondylitis and HL-A27. Lancet. 1973;i:904–907. - PubMed
    1. Brown MA, Pile KD, Kennedy LG, Calin A, Darke C, Bell J, Wordsworth BP, Cornelis F. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis. 1996;55:268–270. - PMC - PubMed
    1. Brewerton DA, Caffrey M, Hart FD, James DCO, Nichols A, Sturrock RD. Reiters disease and HL-A27. Lancet. 1974;ii:996–998.
    1. Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology. 2000;118:274–278. - PubMed
    1. Allen RL, Bowness P, McMichael A. The role of HLA-B27 in spondyloarthritis. Immunogenetics. 1999;50:220–227. doi: 10.1007/s002510050596. - DOI - PubMed

Publication types

Substances